Thursday, 20 December 2018

Gilead, Agenus sign deal to develop immuno-oncology therapies

Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)